Medullary Breast Carcinoma

• Medullary Breast Carcinoma is a rare breast cancer subtype with distinct pathological features.
• It typically presents as a palpable mass and is often associated with a favorable prognosis despite its high-grade appearance.
• Symptoms are similar to other breast cancers, but diagnosis relies on specific microscopic findings.
• Treatment usually involves surgery, often followed by chemotherapy and sometimes radiation, tailored to individual patient needs.
• Its unique biological profile, including frequent triple-negative status, guides specific therapeutic strategies.

What is Medullary Breast Carcinoma?

Medullary Breast Carcinoma is a rare form of invasive breast cancer, accounting for approximately 1% to 7% of all invasive breast cancers. It is characterized by a soft, fleshy appearance and distinct microscopic features, including a syncytial growth pattern (cells growing in cohesive sheets), a prominent lymphocytic infiltrate (a large number of immune cells surrounding the tumor), and a lack of glandular or tubular structures. Despite often presenting as a high-grade tumor, Medullary Breast Carcinoma typically has a better prognosis compared to other high-grade invasive ductal carcinomas. This subtype is more commonly observed in younger women and is frequently associated with BRCA1 gene mutations, often presenting as triple-negative breast cancer, meaning it lacks estrogen receptors, progesterone receptors, and HER2 protein overexpression.

Recognizing Medullary Breast Carcinoma Symptoms and Prognosis

The medullary breast cancer symptoms are often similar to those of other breast cancers, typically manifesting as a palpable lump or mass in the breast. This mass is usually well-defined, soft, and movable, though it can sometimes be firm. Other potential symptoms may include changes in breast size or shape, skin dimpling, nipple discharge, or nipple inversion. However, these symptoms are not unique to Medullary Breast Carcinoma, and definitive diagnosis requires a biopsy and pathological examination to identify its characteristic features. The presence of a significant lymphocytic infiltrate is a key diagnostic marker that distinguishes it from other breast cancer types.

The medullary carcinoma breast prognosis is generally considered more favorable than that of typical invasive ductal carcinomas of similar grade. This improved outlook is often attributed to the robust immune response indicated by the dense lymphocytic infiltrate surrounding the tumor, which is thought to help control cancer cell growth. Factors influencing prognosis include tumor size, lymph node involvement, and overall tumor stage. While it often presents as a high-grade tumor, its distinct biological behavior contributes to a relatively good long-term survival rate. For instance, studies indicate that patients with pure medullary carcinoma tend to have higher survival rates compared to those with other forms of invasive ductal carcinoma, even with lymph node involvement.

Treatment Approaches for Medullary Breast Carcinoma

The treatment for medullary breast cancer is typically multidisciplinary and tailored to the individual patient, considering tumor characteristics, stage, and overall health. Surgery is the primary treatment modality, which may involve a lumpectomy (breast-conserving surgery) or a mastectomy (removal of the entire breast), often accompanied by lymph node evaluation (sentinel lymph node biopsy or axillary lymph node dissection). Given that Medullary Breast Carcinoma often presents as triple-negative breast cancer, chemotherapy is a common and effective systemic treatment, frequently administered before (neoadjuvant) or after (adjuvant) surgery.

Radiation therapy may be recommended after lumpectomy or mastectomy, especially if the tumor is large, there is lymph node involvement, or if surgical margins are close or positive. Because Medullary Breast Carcinoma is typically hormone receptor-negative and HER2-negative, hormonal therapy and HER2-targeted therapies are generally not effective. However, ongoing research into targeted therapies for triple-negative breast cancer may offer future treatment options. The specific treatment plan is determined by an oncology team, aiming to maximize efficacy while minimizing side effects.